|
Learn how to use IsoPSA to better determine which patients to defer for biopsy and which to monitor more closely. |
|
BackTable Urology on Going Beyond PSA Testing
|
|
“Patients know that [PSA testing] is not perfect,” says Dr. Jason Hafron, Chief Medical Officer of the Michigan Institute of Urology.
|
|
In a recent episode of the BackTable Urology podcast, Dr. Jason Hafron discusses how he has overcome the limitations of PSA testing by incorporating ancillary testing in his practice. |
|
|
|
|
|
He uses the IsoPSA Test in his clinic because, as multiple clinical studies have demonstrated, “we see a significant reduction in [unnecessary] biopsies…so you are biopsying patients that need it. I think patients appreciate it—going this extra step.”1,2
|
|
He also notes that the IsoPSA Test's longitudinal data shows a single result can help predict future risk for csPCa for up to 30 months3 and explores how the IsoPSA can enhance PI-RADS 1-3 results.4
|
|
|
Receive education updates and resources
|
Subscribe to learn more about the IsoPSA Test and receive updates when new CME programs, webinars, and case studies are available.
-
Abdallah, et al., Urology. 2025 Jan 15:S0090-4295(25)00031-7.
-
Klein, et al., Urol Oncol. 2022 Sep;40(9):408.e9408.e18.
-
Abdallah, et al., Urology Jan15:S0090 4295(25)00031 7.
-
Benidir et al., Urology. 2023 Jun;176:115 120
|
|
|
This material concerns the IsoPSA Test, a laboratory developed test (LDT) from Cleveland Diagnostics, Inc., which is performed by CLIA-certified laboratories qualified to conduct high-complexity clinical testing and is only intended for use consistent with applicable CLIA requirements. When offered as an LDT, the IsoPSA Test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). |
|
|
|
